Hjem
Olav Mellas bilde

Olav Mella

Professor
  • E-postOlav.Mella@uib.no
  • Telefon+47 55 97 20 10+47 55 97 20 69
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • 2020. Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. Frontiers in medicine.
  • 2020. Human Leukocyte Antigen Alleles Associated With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Scientific Reports. 1-8.
  • 2019. B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 585-593.
  • 2018. Rituximab serum concentrations and anti-rituximab antibodies during B-cell depletion therapy for myalgic encephalopathy/chronic fatigue syndrome. Clinical Therapeutics. 9.
  • 2018. Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Molecular Neurobiology. 1-9.
  • 2017. Consolidative radiotherapy to residual masses after chemotherapy is associated with improved outcome in diffuse large B-cell lymphoma. A retrospective, population-based study. Clinical Lymphoma, Myeloma & Leukemia. 125-135.
  • 2016. Serum BAFF and APRIL levels, T-lymphocyte subsets, and immunoglobulins after B-cell depletion using the monoclonal anti-CD20 antibody rituximab in myalgic encephalopathy/chronic fatigue syndrome. PLOS ONE.
  • 2016. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight.
  • 2016. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain, behavior, and immunity. 32-39.
  • 2015. B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. PLOS ONE.
  • 2013. Early rehabilitation of cancer patients - a randomized controlled intervention study. BMC Cancer. 7 sider.
  • 2012. Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update. International Journal of Hyperthermia. 549-553.
  • 2011. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLOS ONE. 13 sider.
  • 2009. cDNA microarray analysis of serially sampled cervical cancer specimens from patients treated with thermochemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics. 1562-1569.
  • 2009. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicenter randomized trial by The European Society for Hyperthermic Oncology. International Journal of Hyperthermia. 323-334.
  • 2009. Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurology. 7 sider.
  • 2009. CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989-2003. American Journal of Neuroradiology. 744-751.
  • 2008. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 435-442.
  • 2008. AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003. BMC Cancer. 8 sider.
  • 2004. Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway. Supportive Care in Cancer. 312-318.
  • 2004. Tilbud om komplementærbehandling i sykehus. Tidsskrift for Den norske legeforening. 3078-3080.
  • 2004. Tilbud om komplementær behandling i sykehus? Tidsskrift for Den norske legeforening. 3078-3080.
  • 2004. Pigmented astrocytoma with suprasellar location: case report and literature review. Acta Neuropathologica. 461-466.
  • 2004. Knowledge of and attitudes toward complementary and alternative therapies: a national multicentre study of oncology professionals in Norway. European Journal of Cancer. 529-535.
  • 2004. Incidence, Clinical Features, Treatment and Outcome of Primary Central Nervous System Lymphoma in Norway. Acta Oncologica. 520-529.
  • 2003. Skal alternative utøvere behandle kreft - hva mener onkologiske helsearbeidere? Tidsskrift for Den norske legeforening. 3059-3061.
  • 2003. Should alternative therapists treat cancer-what is the opinion of oncology health personnel? Tidsskrift for Den norske legeforening. 3059-3061.
  • 2003. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 3840-3848.
  • 2002. Norwegian Oncologists' Expectations of Intensity-modulated Radiotherapy. Acta Oncologica. 562-565.
  • 2001. Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiotherapy and Oncology. 313-320.
  • 2001. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment. 111-116.
  • 2001. Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiotherapy and Oncology. 147-154.
  • 2000. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 645-652.
  • 2000. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 645-652.
  • 1999. Status of clinical hyperthermia. Acta Oncologica. 863-873.
  • 1998. Kinetics of total plasma homocysteine during basal conditions. Clinical Chemistry. 1886-1891.
  • 1998. Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • 1998. Intravenous infusion of glucose and the vasodilator sodium nitroprusside in combination with local hyperthermia: Effects on tumour pH and tumour re in the BT4An rat tumour model. International Journal of Hyperthermia. 403-416.
  • 1998. Intravenous infusion of glucose and the vasodilator sodium nitroprusside in combinaiton with local hyperthermia: Effects on tumour pH and tumour response in the BT(4)AN rat tumour model. International Journal of Hyperthermia. 403-416.
  • 1997. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomized double-blind, the "nordic" phase III st. British Journal of Cancer. 270-277.
  • 1996. Use of the vasodilator sodium nitroprusside during local hyperthermia: Effects on tumor temperature and tumor response in a rat tumor model. International Journal of Radiation Oncology, Biology, Physics. 403-415.
  • 1996. Høydosebehandling med autolog stamcellestøtte ved maligne lidelser. Tidsskrift for Den norske legeforening. 2577-2281.
  • 1996. Høydosebehandling med autolog stamcellestøtte ved maligne lidelser. Tidsskrift for Den norske legeforening. 2577-81.
  • 1996. Effect of sodium nitroprusside-induced hypotension on the blood flow in subcutaneous and intramuscular BT4AN tumors and normal tissues in rats. International Journal of Radiation Oncology, Biology, Physics. 393-401.
  • 1996. Effect of sodium nitroprusside-induced hypotension on the blood flow in subcutaneous and intramuscular BT(4)AN tumors and normal tissues in rats. International Journal of Radiation Oncology, Biology, Physics. 393-401.
  • 1996. ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease. Acta Oncologica. 73-80.
  • 1995. Timing of hypertonic glucose and thermochemotherapy in the BT%eAn rat glioma: Relation to intratumoral pH reduction and circulatory changes after glucose supply. International Journal of Radiation Oncology, Biology, Physics. 409-416.
  • 1995. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. The Lancet. 540-543.
  • 1995. Hypertermi: Biologi - Fysik - Klinik. Helsetjeneste, Medisinsk Teknikk, Økonomi, Ledelse. 21-27.
Rapport
  • 1995. Høydosebehandling med autolog stamcellestøtte ved maligne lidelser. Instilling fra rådgivende gruppe nedsatt av Helsedirektoratet, senere Statens Helsetilsyn. .
Vitenskapelig foredrag
  • 2014. “The prevalence of distress, emotional reactivity, fatigue and health related quality of life among newly diagnosed cancer patients starting adjuvant treatment”.
  • 2003. Trimodality treatment with regional hyperthermia, radiotherapy and chemotherapy in primary inoperable or recurrent rectal carcinoma.
  • 2003. Trimodality treatment of inoperable/locally recurrent rectal cancer with hyperthermia, radiotherapy and chemotherapy. Pilot studies.
  • 2003. Regional hyperthermia in addition to chemoradiotherapy in cervical carcinoma: Results of a phase II study.
  • 2003. Regional hyperthermia in addition to chemoradiotherapy in cervical cancer: results of a phase II-study.
  • 2003. Regional hyperthermia added to chemoradiotherapy in advanced cervical cancer: Multicenter international feasibility.
Leserinnlegg
  • 2018. Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon . Tidsskrift for Den norske legeforening. 12-13.
  • 2017. Mer om pyruvat dehydrogenase og kronisk utmattelsessyndrom. Tidsskrift for Den norske legeforening.
  • 2017. Chronic fatigue syndrome and pyruvate dehydrogenase function. Tidsskrift for Den norske legeforening.
  • 2002. Hyperthermia alone or combined with cisplatin in addition to radiotherapy for advanced uterine cervical cancer. International Journal of Hyperthermia. 25-30.
Vitenskapelig kommentarutgave
  • 2018. Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon.
Fagbok
  • 1999. Cytostatika Medikamentell kreftbehandling kap. 8 Kvalme og oppkast ved cytostatikabehandling. Institutt for farmakoterapi og Den Norske Kreftforening.
Kronikk
  • 1997. Når ansvarsfraskrivelse blir arbeidsform. [Kronikk]. Aftenposten (morgenutg. : trykt utg.).
  • 1997. Fremtidens kreftbehandling. [Kronikk]. Bergens Tidende.
  • 1996. Dagbladet på ville veier. Dagbladet. 3.
Doktorgradsavhandling
  • 1990. Optimization of hyperthemia and chemotherapy in an experi- mental brain tumour model.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • 2009. Myelomatose. 11 sider.
  • 1999. Myelomatose. 5 sider.
  • 1999. Kvalme og oppkast ved cytostaticabehandling. 8 sider.
Sammendrag/abstract
  • 2014. Particle therapy in Norway - report from the national project group. Radiotherapy and Oncology. 314-314.
Poster
  • 2003. Regional hyperthermia added to chemoradiotherapy in advanced cervical cancer: Multicenter international feasibility.
  • 2001. Regional Hyperthermia as part of trimodality treatment of locally advanced/locally recurrent cervical carcinoma, and primarily inoperable/locally recurrent carcinoma.
  • 2001. National survey of IMRT expectations in Norway.

Se fullstendig oversikt over publikasjoner i CRIStin.